Variance in 10-Year Fracture Risk Calculated With and Without T-Scores in Select Subgroups of Normal and Osteoporotic Patients

被引:26
作者
Hamdy, Ronald C. [2 ,3 ]
Kiebzak, Gary M. [1 ]
机构
[1] St Lukes Episcopal Hosp, Ctr Orthopaed Res & Educ, Houston, TX 77030 USA
[2] VAMC, Johnson City, TN USA
[3] E Tennessee State Univ, Osteoporosis Ctr, Johnson City, TN 37614 USA
关键词
FRAX; Osteoporosis; Risk assessment; 10-year fracture risk; VERTEBRAL FRACTURES; WOMEN; ALENDRONATE; RISEDRONATE; DENSITY;
D O I
10.1016/j.jocd.2008.12.003
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
The World Health Organization fracture risk assessment tool (FRAX) uses clinical risk factors to predict the patient's 10-yr probability of sustaining a hip or other major osteoporosis-related fracture. Inclusion of the femoral neck T-score is optional in the calculation. We evaluated the impact of including the T-score in the calculation of fracture risk and resultant treatment recommendation. We retrospectively reviewed charts of 180 white women scanned on a Hologic dual-energy X-ray absorptiometry (DXA). FRAX scores were calculated with T-scores (FRAX+) and without T-scores (FRAX-). We compared the National Osteoporosis Foundation (NOF) treatment recommendations (>= 20% risk of a major osteoporotic fracture or >= 3% risk of hip fracture for osteopenic patients) between FRAX+ and FRAX- scores. Agreement between FRAX+ and FRAX- was 89.4%. Disagreement occurred in 2 distinct subgroups of patients (10.6% of cases), that is, FRAX+ scores exceeded the NOF recommended treatment thresholds and FRAX- scores did not. or vice versa. One subgroup comprised older patients with normal T-scores for whom FRAX- scores exceeded the treatment threshold. The second subgroup comprised younger patients with high body mass index (BMI) and low T-scores for whom FRAX- scores did not exceed the treatment threshold. FRAX scores generated without T-scores may lead to treatment recommendations for patients who have normal bone mineral density and no treatment recommendations for patients who have osteoporosis. T-scores should be used for optimal application of FRAX.
引用
收藏
页码:158 / 161
页数:4
相关论文
共 11 条
[1]
Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures - Results from the fracture intervention trial [J].
Cummings, SR ;
Black, DM ;
Thompson, DE ;
Applegate, WB ;
Barrett-Connor, E ;
Musliner, TA ;
Palermo, L ;
Prineas, R ;
Rubin, SM ;
Scott, JC ;
Vogt, T ;
Wallace, R ;
Yates, AJ ;
LaCroix, AZ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (24) :2077-2082
[2]
Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA [J].
Dawson-Hughes, B. ;
Tosteson, A. N. A. ;
Melton, L. J., III ;
Baim, S. ;
Favus, M. J. ;
Khosla, S. ;
Lindsay, R. L. .
OSTEOPOROSIS INTERNATIONAL, 2008, 19 (04) :449-458
[3]
Treatment with alendronate prevents fractures in women at highest risk - Results from the fracture intervention trial [J].
Ensrud, KE ;
Black, DM ;
Palermo, L ;
Bauer, DC ;
BarrettConnor, E ;
Quandt, SA ;
Thompson, DE ;
Karpf, DB .
ARCHIVES OF INTERNAL MEDICINE, 1997, 157 (22) :2617-2624
[4]
Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene -: Results from a 3-year randomized clinical trial [J].
Ettinger, B ;
Black, DM ;
Mitlak, BH ;
Knickerbocker, RK ;
Nickelsen, T ;
Genant, HK ;
Christiansen, C ;
Delmas, PD ;
Zanchetta, JR ;
Stakkestad, J ;
Glüer, CC ;
Krueger, K ;
Cohen, FJ ;
Eckert, S ;
Ensrud, KE ;
Avioli, LV ;
Lips, P ;
Cummings, SR .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (07) :637-645
[5]
Bisphosphonate therapy and vascular calcification [J].
Goldstein, MR .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (11) :1424-1425
[6]
FRAX™ and the assessment of fracture probability in men and women from the UK [J].
Kanis, J. A. ;
Johnell, O. ;
Oden, A. ;
Johansson, H. ;
McCloskey, E. .
OSTEOPOROSIS INTERNATIONAL, 2008, 19 (04) :385-397
[7]
EFFECT OF ORAL ALENDRONATE ON BONE-MINERAL DENSITY AND THE INCIDENCE OF FRACTURES IN POSTMENOPAUSAL OSTEOPOROSIS [J].
LIBERMAN, UA ;
WEISS, SR ;
BROLL, J ;
MINNE, HW ;
QUAN, H ;
BELL, NH ;
RODRIGUEZPORTALES, J ;
DOWNS, RW ;
DEQUEKER, J ;
FAVUS, M ;
SEEMAN, E ;
RECKER, RR ;
CAPIZZI, T ;
SANTORA, AC ;
LOMBARDI, A ;
SHAH, RV ;
HIRSCH, LJ ;
KARPF, DB .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (22) :1437-1443
[8]
Effect of risedronate on the risk of hip fracture in elderly women [J].
McClung, MR ;
Geusens, P ;
Miller, PD ;
Zippel, H ;
Bensen, WG ;
Roux, C ;
Adami, S ;
Fogelman, I ;
Diamond, T ;
Eastell, R ;
Meunier, PJ ;
Reginster, JY ;
Wasnich, RD ;
Greenwald, M ;
Kaufman, J ;
Chestnut, CH .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (05) :333-340
[9]
Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis [J].
Reginster, JY ;
Minne, HW ;
Sorensen, OH ;
Hooper, M ;
Roux, C ;
Brandi, ML ;
Lund, B ;
Ethgen, D ;
Pack, S ;
Roumagnac, I ;
Eastell, R .
OSTEOPOROSIS INTERNATIONAL, 2000, 11 (01) :83-91
[10]
Assessment of 10-year absolute fracture risk: a new paradigm with worldwide application [J].
Siris, E. ;
Delmas, P. D. .
OSTEOPOROSIS INTERNATIONAL, 2008, 19 (04) :383-384